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1 ABSTRACT 
Background: Cardio-vascular diseases (CVD), their well established risk factors (CVRF) and mental 
disorders are common and co-occur more frequently than would be expected by chance. However, the 
pathogenic mechanisms and course determinants of both CVD and mental disorders have only been 
partially identified. 
Methods/Design: Comprehensive follow-up of CVRF and CVD with a psychiatric exam in all 
subjects who participated in the baseline cross-sectional CoLaus study (2003-2006) (n=6'738) which 
also included a comprehensive genetic assessment. The somatic investigation will include a shortened 
questionnaire on CVRF, CV events and new CVD since baseline and measurements of the same 
clinical and biological variables as at baseline. In addition, pro-inflammatory markers, persistent pain 
and sleep patterns and disorders will be assessed. In the case of a new CV event, detailed information 
will be abstracted from medical records. Similarly, data on the cause of death will be collected from the 
Swiss National Death Registry. The comprehensive psychiatric investigation of the 
CoLaus/PsyCoLaus study will use contemporary epidemiological methods including semi-structured 
diagnostic interviews, experienced clinical interviewers, standardized diagnostic criteria including 
threshold according to DSM-IV and sub-threshold syndromes and supplementary information on risk 
and protective factors for disorders. In addition, screening for objective cognitive impairment will be 
performed in participants older than 65 years. 
Discussion: The combined CoLaus/PsyCoLaus sample provides a unique opportunity to obtain 
prospective data on the interplay between CVRF/CVD and mental disorders, overcoming limitations 
of previous research by bringing together a comprehensive investigation of both CVRF and mental 
disorders as well as a large number of biological variables and a genome-wide genetic assessment in 
participants recruited from the general population. 
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2 BACKGROUND 
Cardiovascular diseases (CVD) and mental disorders co-occur more frequently than would be expected 
by chance 1;2, but the reasons for this association are poorly understood.  
Several studies have documented that the prevalence of depression is increased among patients with 
coronary artery disease (CAD) 3;4. An even larger percentage of patients with CAD has subthreshold 
depressive syndromes 5, which have been associated with increased mortality 6. Similarly, depression 
occurs in 20 to 50% of patients after an acute stroke 7, and the development of depression is associated 
with a poor functional prognosis and a negative impact on the patient’s quality of life 7;8. Population-
based prospective studies of individuals with depression or depressive symptoms documented 
increased CVD morbidity and mortality in these individuals 1;4;7. Two studies that included 
subthreshold depressive syndromes also suggested an association between these syndromes and 
myocardial infarction or cardiac mortality 9;10. CAD was associated more strongly with major 
depressive disorder than with subthreshold depression, which suggests a dose response-relationship 
between depression and the development of CAD 11. However, the large majority of these 
epidemiological studies relied on depression scales or self-rating questionnaires for depression, rather 
than on diagnostic interviews. These studies also did not take into account potential effects of 
comorbid mental disorders such as anxiety or substance use disorders. In their review and meta-
analysis, van der Kooy et al. 1 could identify only four prospective community studies based on a 
standardized clinical interview to diagnose depression with respect to subsequent CVD risk: three 
assessed the relationship between depression and the risk of coronary heart disease 9;10;12 and one the 
relationship between depression and stroke 13. As these studies could not or could only partially adjust 
for the presence of established physical or behavioral cardiovascular risk factors (CVRF), the role of 
depression as an independent risk factor for CVD is debatable 4. 
Several studies also suggested that anxiety symptoms, "worry" and specific anxiety disorders may 
influence the prognosis in patients with established coronary heart disease and promote the 
development of cardiovascular events in healthy participants 2;14. However, with the exception of the 
study of Weissman et al. 15, existing research was based on anxiety scales and not on structured 
psychiatric interviews designed to assess the four major subtypes of anxiety disorders (panic disorder, 
generalized anxiety disorder, agoraphobia and social phobia). Hence, whether there is an unspecific 
effect of anxiety or worry related to all forms of anxiety disorders or, alternatively, whether specific 
anxiety disorders are differentially associated with CVD remains an open question 16. 
Finally, mental disorders have been associated with CVRF such as heavy smoking, diabetes 17;18, insulin 
resistance 19 and obesity 20;21. Similarly, prospective cohort studies found ApoE4, hypertension during 
mid-life, heart failure, smoking, adiposity, increased cholesterol blood level and diabetes to be 
associated with an increased risk for Alzheimer’s disease 22, vascular dementia 23;24 and mild cognitive 
impairment 25, but the precise impact of CVRFs on cognitive function awaits further investigation. 
Hence, the primary aim of this study is to prospectively assess the complex interplay between CVD, 
CVRF and mental disorders, based on the follow-up of a large population-based cohort with a 
comprehensive somatic, psychiatric and genetic investigation at baseline. The main research questions 
are 1) Do mental disorders increase vulnerability to CVRF and CVD? 2) Do CVRF and CVD or their 
drug treatment promote the development of mental disorders? and 3) Do CVRF/CVD and mental 
disorders share common pathogenic processes? 
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3 METHODS / DESIGN 
The cohort includes all participants of the original CoLaus sample (n = 6'738) 26, a majority of which 
also underwent a thorough psychiatric examination 27. A first 5-year follow-up combining a 
comprehensive CVRF and CVD assessment with a psychiatric exam is currently ongoing and further 
follow-up investigations are planned in a five-year rhythm. This protocol describes details of the first 
follow-up (2009-2012) 
3.1 INCLUSION AND EXCLUSION CRITERIA 
Inclusion criteria: participation in the baseline CoLaus study 26 and willingness to participate to the 
follow-up. 
Exclusion criteria: refusal to participate, having moved too far away to come to the somatic exam at 
the CHUV in Lausanne, insufficient ability to speak French or English (for the psychiatric part only). 
3.2 CONTACT AND FOLLOW-UP 
All participants of the baseline examination received an information brochure summarizing the 
preliminary study results; in case of returned mail, information from phone companies or the 
population register of the City of Lausanne was used to find the new address of the participant or to 
confirm that the participant has died. In order to maximize follow up, letters and brochures will be 
sent to participants at six-month intervals. Six months before the intended follow-up interview, a letter 
describing the goals of the follow-up, the requirements for participation and the importance of their 
contribution to long-term efforts in disease prevention, has been sent to participants. In a second step, 
participants will be contacted by phone to provide further information on the study. Prior to the 
follow-up interview, participants will receive the detailed information letter and consent forms. Figure 
1 summarizes the different steps to contact participants. 
Given that more than 95% of CoLaus participants indicated that they were willing to take part in the 
follow-up, we expect a sample of 6'000 participants between 40 to 80 years of age taking part in the 
somatic exam (and 4'000 to both the somatic and psychiatric exam). We expect that approximately 
3'500 participants will have the combined evaluation at baseline and at follow-up. For the second (i.e. 
10-year) follow-up, we expect a sample of about 5'400 individuals for the somatic exam and a 
subsample of 3'600 with at least two psychiatric evaluations. The increased sample size for the 
subsample with combined somatic and psychiatric evaluations at the 10-year follow-up is due to the 
inclusion of the 65 to 75 year-old participants at baseline in the psychiatric evaluation at the 5-year 
follow-up. As demographic data of all the residents of the city of Lausanne in the age range of interest 
are known, the demographic characteristics of participants and non-participants can be compared. 
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Figure 3. Flowchart for the follow-up of the CoLaus/PsyCoLaus participants. 
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3.3 CLINICAL (SOMATIC) ASSESSMENT 
Similarly to the baseline evaluation 26, the follow-up somatic investigation will be conducted at the 
CHUV in Lausanne and will include an interview, a physical exam, blood and urine collections as well 
as a list of questionnaires with supplementary information on self-report dietary habits, physical 
activity, sleep patterns and disorders. Additional information will be abstracted from the medical 
records or collected from the death registry, whenever appropriate. We will use the same definitions 
for CVRF at follow-up as at baseline, in order to determine the incidence of these CVRF. 
Weight, height, waist and hip circumferences, percent body fat (bioimpedance), blood pressure and 
heart rate will be measured. Blood will be taken in the fasting state and analyses be performed at the 
Central Chemistry Laboratory and the Laboratory of Endocrinology of the CHUV. Most of the blood 
and urine markers will be identical to those measured at baseline (Table 1). Aliquots of plasma, serum 
and urine will be stored at -80oC for future analyses. The following definitions will be applied: 
overweight, body mass index (BMI) ≥ 25kg/m2; obesity: BMI ≥30 kg/m2; hypertension, blood 
pressure ≥ 140/90 mmHg and/or presence of anti-hypertensive drug treatment; low HDL cholesterol, 
(<1 mmol/L in men and <1.29 mmol/L in women); high LDL cholesterol: ≥ 4.1 mmol/L; high 
triglyceride, ≥ 2.2 mmol/L. Dyslipidemia will be defined by low HDL cholesterol and/or high 
triglyceride and/or LDL cholesterol ≥ 4.1 mmol/L or ≥ 2.6 mmol/L in presence of self-reported 
myocardial infarction, stroke, coronary artery disease or diabetes. Diabetes will be defined by fasting 
plasma glucose ≥ 7 mmol/L and/or presence of oral hypoglycaemic or insulin treatment. 
Dietary intake will be assessed with a self-administered semi quantitative food frequency questionnaire 
which covers the 4 weeks prior to the day of data collection. The questionnaire was developed and 
validated in the general adult population of Geneva, Switzerland 28;29). It includes a list of about 80 
food items and their serving sizes, and food intake data can be converted into daily energy and nutrient 
intakes. 
Physical activity will be assessed with a validated, self-administered quantitative physical activity 
frequency questionnaire developed in the Geneva general adult population 30. The questionnaire covers 
the last 7 days prior to the day of data collection. The French version 31 of the Center for 
Epidemiologic Studies Depression Scale (CES-D) 32, a 20 item instrument will be used to assess the 
severity of self-report depressive symptoms over the past week on a 4-point scale.  
Cognitive function will be assessed by the Mini Mental State Examination (MMSE) 28;33. The test is 
used to screen for cognitive deficiency, to evaluate its intensity and to measure changes in states of 
confusion and dementia in older participants; the French translation has been validated 34. 
Sleep disorders will be assessed by a series of questionnaires. Daytime sleepiness will be assessed by the 
Epworth Sleepiness scale (ESS) 35, a self-administered questionnaire measuring the participant’s general 
level of daytime sleepiness. ESS scores distinguish normal participants from patients in various 
diagnostic groups including those with obstructive sleep apnea syndrome, narcolepsy and idiopathic 
hypersomnia. Sleep apneas will be assessed by the Berlin questionnaire 36, which surveys the presence 
and frequency of snoring, daytime sleepiness or fatigue and high blood pressure. Circadian typology 
(i.e. “morningness” and “eveningness” of the participants) will be assessed by the validated French 
translation 37 of the Horne-Ostbergs Morningness-Eveningness Score 38. Narcolepsy will be assessed 
by the Ullanlinna Narcolepsy Scale 39, an eleven item, self-administered questionnaire. Sleep quality and 
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disorders for the month preceding the evaluation will be assessed by the Pittsburgh Sleep Quality 
Index (PSQI) 40, a self-administered questionnaire on participant’s sleep quality, sleep duration, 
efficiency, use of hypnotics and poor daytime functioning. 
The presence of restless leg syndrome (RLS) will be screened using a self-administered questionnaire 
based on the 4 basic diagnostic criteria of RLS developed during and international workshop and 
approved by the International Restless Legs Syndrome Study Group 41. 
Persistent pain will be screened with the self administered TNS Sofres questionnaire 42 assessing the 
presence of pain for more than 3 months and its localization. This instrument has already been applied 
in a population based study 43. 
3.4 PSYCHIATRIC ASSESSMENT 
All interviews will be carried by psychologists or psychiatrists. The interviewers demonstrated an 
adequate inter-rater reliability following individualized training. This includes ratings of tapes and 
supervised co-ratings of live participants. In order to provide ongoing supervision throughout the 
study, each interview will be reviewed by an experienced psychiatrist or psychologist. 
Diagnostic assessment will be performed by the follow-up version of the Diagnostic Interview for 
Genetic Studies (DIGS) 44. This instrument is a shortened interim diagnostic interview based upon the 
chapters of the original DIGS to collect information on psychopathological manifestations and 
psychotherapeutic and drug treatment during the follow-up period. The DIGS elicits a wide spectrum 
of DSM-IV Axis I criteria including mood, anxiety, psychotic and specific substance use disorders as 
well as suicidal behavior. The French version of the DIGS was established in a collaborative effort 
from sites in France (INSERM, Paris) and Switzerland. Inter-rater and test-retest reliability of the 
French version were established in a clinical sample in Lausanne 45. Excellent inter-rater reliability was 
found for schizophrenia, bipolar disorder, major depression and unipolar schizoaffective disorder 
while fair inter-rater reliability was demonstrated for bipolar schizoaffective disorder (Table 1). High 
kappa coefficients for inter-rater reliability and slightly lower kappas for test-retest reliability were also 
found for drug and alcohol use disorders as well as for antisocial personality diagnoses 46. Reliability 
was also established for subthreshold depressive (Yule's Y=0.91) and manic (Yule's Y=0.89) 
syndromes.  
The measurement of cognitive functioning in participants aged 65 to 80 years will rely on several 
instruments. Subjective cognitive complaints will be assessed using the Cognitive Complaint 
Questionnaire 47. Objective cognitive assessment will comprise a series of specifically designed tests to 
ascertain a wide range of cognitive functions taking into account both education and age-related 
performance: Do 80 (Epreuve de dénomination orale d’images) 48, Grober and Buschke episodic 
memory test 49, CERAD praxis items 50, lexical and semantic fluency tasks 51 and Stroop color test 52. 
Severity staging will be performed using the Clinical Dementia Rating (CDR) 53. 
Migraine will be assessed by the 'Diagnostic Interview for Headache Syndromes' (DIHS) and the 
specific headache subtypes will be characterized according to the criteria of the International Headache 
Society 54. This instrument was developed by Merikangas et al. as part of an international collaborative 
study of chronic daily headache 55. 
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Life events that have occurred since the first investigation will be assessed by the short interview of F. 
Amiel-Lebigre 56. In addition, subjects will complete a self-report battery including the Symptom 
Check List 90 Revised (SCL-90 R) 57, the Type D Scale (DS14) 58, the Hypomania Checklist (HCL-32-
R1) 59, the Social Support Questionnaire (SQQ6) 60, the Manchester Short Assessment of Quality of 
Life (MANSA) questionnaire 61 and the Revised NEO Personality Inventory (NEO-FFI-R) 62. 
At the end of the interview, participants will receive little swabs (Salivettes, Sarstedt, Leicester, UK) to 
be used for salivary cortisol collection the next working day at awakening, 30 minutes thereafter, at 
11:00 a.m. and at 8:00 p.m. Free cortisol levels will be assessed using a chemiluminescence assay as 
described previously 63;64. The list of all the psychiatric tools to be used is summarized in table 2. 
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Table 1 Somatic assessment at baseline and follow-up 
Module Variable Baseline Follow-up 
1. Interview a. Age, gender, origin, ethnicity (up to grandparents) 
b. Education level, occupation, socio-economic status 
c. Smoking, alcohol intake, physical activity 
d. Personal and family history of CVD, hypertension, diabetes, stroke, myocardial infarction, and 
coronary procedures or surgery. 
e. Current medication (over the counter or prescription) 
f. Diagnostic Interview for Headache Syndromes (DIHS) / Migraine 
X 
X 
X 
 
X 
X 
X 
 
 
X 
 
X 
X 
X 
2. Physical exam a. Height, weight, waist and hip circumference 
b. Blood pressure (triplicate measurement with automated device), heart rate 
c. Percent fat (bio impedance) 
X 
X 
X 
X 
X 
X 
3. Blood (fasting) a. Markers of diabetes and insulin resistance: glucose, insulin, leptin, adiponectin 
b. Makers of dyslipidemia: total, HDL and LDL-cholesterol, triglycerides, LDL-size1, ApoB1 
c. Biomarkers associated with increased CVD risk: CRP, homocystein1, TNF-α2, IL-62, IL-1β2 
d. Markers of co-morbid conditions: 
i. Liver function tests: ASAT, ALAT, γ-GT, alkaline phosphatase 
ii. Renal function: creatinine 
iii. Chronic elevated alcohol consumption: carbohydrate deficient transferin 
iv. Others: uric acid, calcium, albumin1, total proteins 
e. Blood count 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
4.  Urine a. Microalbuminuria, Creatinine X X 
5. Saliva a. Four salivary cortisol measures  X 
1 only baseline;   2 retrospectively assessed for baseline 
ALAT, Alanine Aminotransferase; ApoB, apolipoprotein B; ASAT, Aspartate Aminotransferase; CRP, C-reactive protein; CVD, cardiovascular disease; γ-
GT, gamma-glutamyl transpetidase; HDL, high-density lipoprotein; IL, interleukin; LDL, low-density lipoprotein; MMSE, Mini-Mental State Examination; 
TNF-α , Tumor Necrosis Factor-alpha  
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Table 2 Psychiatric assessment tools at baseline and follow-up. 
Module Instrument / Assessed domain Baseline Follow-up 
1. Interview a. Diagnostic Interview for Genetic Studies (DIGS) / DSM-IV Axis-I diagnoses 
b. Short interview of F. Amiel-Lebigre / Life events 
c. Family History-Research Diagnostic Criteria (FH-RDC) / DSM-IV Axis-I diagnoses in 1st-degree relatives 
X 
X 
X 
X 
X 
 
3. Cognitive tests a. Mini Mental State Examination (MMSE) 
b. Cognitive Complaint Questionnaire 
c. Do 80 (Epreuve de dénomination orale d’images) 
d. CERAD praxis items 
e. Stroop color test 
f. Clinical Dementia Rating (CDR) 
X X 
X 
X 
X 
X 
X 
4. Self ratings a. General Health Questionnaire, 12 question version (GHQ-12) / Screening of psychiatric disorders 
b. State-Trait Anxiety Inventory (STAI) / Anxiety level 
c. Retrospective Self Report Childhood Inhibition (RSRCI) / Childhood inhibition 
d. Dimensions of Temperament Survey (DOTS) and DOTS Revised (DOTS-R) / Temperament 
e. Eysenck Personality Questionnaire (EPQ) / Personality dimensions 
f. Type A / Type A behavior 
g. Sensitivity to Reward (STR) / Sensitivity to reward 
h. Parental Bonding Instrument(PBI-M, PBI-F) / Perception of parenting style 
i. FACES III / Family adaptability and cohesion 
j. Dyadic Adjustment Scale (DAS) / Marital adjustment 
k. Family Attitude Scale (FAS-30) / Emotional climate in family 
l. Euronet: Problem Resolution Strategy / Coping 
m. MOS-Sleep Module / Quality of sleep 
n. Center for Epidemiologic Studies Depression Scale (CES-D) / Depression symptoms 
o. Symptom Check List 90 Revised (SCL-90 R) / Psychiatric symptoms 
p. Hypomania Checklist (HCL-32-R1) / Hypomania symptom screening 
q. Revised NEO Personality Inventory (NEO-FFI-R) / Personality dimensions 
r. Type D Scale (DS14) / Type D behavior 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
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s. Social Support Questionnaire (SQQ6) / Social support 
t. Manchester Short Assessment of Quality of Life (MANSA) / Quality of life 
X 
X 
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3.5 VALIDATION OF INCIDENT EVENTS 
If a participant indicates that she/he was treated during the follow-up interval, relevant diagnostic and 
treatment information will be elicited from the patient’s physician or hospital medical records including 
information from coronary angiogram procedures, coronary artery bypass surgery or peripheral artery 
disease. The diagnosis of specific CVD will rely on the following definitions: 
• Myocardial Infarction: hospital discharge diagnosis (HDD) indicating typical ECG and elevated 
myocardial enzymes. 
• Acute coronary syndromes: HDD providing evidence of typical electrocardiographic changes or 
coronary angiogram or history of percutaneous transluminal coronary angioplasty. 
• Stroke: HDD describing the occurrence of new neurologic deficits lasting more than 24 hours. 
All medical records compatible with CVD will be thoroughly reviewed by a cardiologist. Diagnosis of 
CVD will be based on all available information and established by a local adjudication committee 
according to international recommendations 65. In case of doubts, senior physicians who have been 
involved in the participant's treatment will be contacted for the collection of additional information 
and reviewed by the local adjudication committee. 
Deaths within the cohort will be determined every year comparing the CoLaus database with the 
Lausanne City Registry of inhabitants. Information on the cause of death will be elicited from the 
Swiss National Death Registry and, if available, from primary care physicians or hospital charts. 
Complementary data will be collected from relatives where necessary. The definition of CVD death 
will encompass fatal MI, stroke, fatal cardiac arrhythmia, peripheral artery disease (aortic dissection). 
3.6 MANAGEMENT 
The coordination of the ascertainment of participants as well as the progress of data analyses will be 
monitored by several committees: 
• The local steering committee will be in charge of data collection and data management including 
the training and supervision of staff involved in the ascertainment of participants. 
• The scientific committee will include all investigators. The scientific committee will meet twice a 
year and be in charge of the scientific aspects of the project and ensure its multicenter character. 
Specifically, this committee will a) decide on the timing and distribution of analyses across 
centers; b) supervise the local steering committee to ensure recruitment progression and c) 
evaluate the feasibility and scientific value of complementary subprojects submitted by 
researchers from outside, intending to use parts of collected follow-up data. 
• An international advisory board will include all principal investigators as well as international 
specialists with a large scientific expertise in cardiovascular and psychiatric epidemiology or 
population genetics. The international advisory board will meet once a year to monitor the 
scientific progression of the project and to enhance international collaboration. 
  17 
3.7 STATISTICAL POWER ANALYSES 
The power calculations for the associations between psychiatric risk factors at baseline and 
cardiovascular outcomes (CVRF or CVD) are summarized in table 3. Power calculations were based 
on the formula for dichotomous variables 66. We assume a two-tailed p-value of 0.05 and an attrition of 
10% per follow-up resulting in a sample of 3'400 individuals at the 5-year and 3'600 individuals at the 
10-year follow-up. These calculations take into account a 45% prevalence of lifetime diagnosis of 
depression at baseline. As participants already presenting with specific CVRF at baseline need to be 
excluded from these analyses, the calculated sample size was reduced accordingly (i.e. 15.7% for 
obesity, 36.7% for hypertension, 34.2% for dyslipidemia and 6.6% for diabetes). Moreover, the 
expected occurrence of new specific CVRF during the follow-up interval was calculated under the 
assumption that age-specific prevalence rates of CVRF at follow-up in non-depressed individuals 
remain the same as those at baseline, whereas the estimation of cardiovascular events was based on the 
recalibrated Framingham risk function 67. The results indicate that after a 5-year follow-up, an 
association between depression at baseline and a 1.5-fold increased risk for the occurrence of 
hypertension or dyslipidemia in depressed individuals could be detected with a probability of more 
than 80%. For obesity and diabetes, the statistical power will be nearly 80% if the relative risk is at least 
1.75. Regarding CVD, a doubled risk in depressed individuals at baseline would be detected with a 
probability of 72%. For a 10-year follow-up, a 1.5-fold increased risk for the four CVRF could be 
detected with probabilities ranging between 73% (obesity) and 100% (hypertension). A 1.75-fold and a 
two-fold increase of CVD events in depressed participants could be detected with probabilities of 80% 
and > 90%, respectively. Given that the three previous prospective studies 1;4;7 based on diagnostic 
interviews found at least a two-fold increased risk for CVD in depressive individuals, there is a 
satisfactory probability that such an increase in risk could be detected at the first follow-up 
examination. Similarly, a two-fold increased risk for diabetes 68 and obesity 69 in depressed participants 
has been reported, suggesting that this study has a high probability to detect such relationships at least 
at the second follow-up. 
The power calculations for the associations between CVRF and CVD at baseline and incidence of 
psychiatric outcomes are summarized in table 4. The power calculation was based on the formula for 
dichotomous variables 66. We assumed a two-tailed p-value of 0.05 and an attrition of 10% per follow-
up. The power calculations were also based on the baseline prevalence of specific CVRF and 
participants with a lifetime diagnosis of depression at baseline (45%) were excluded from these 
analyses, resulting in a sample of 1'870 participants at the 5-year and 1'925 participants at the 10-year 
follow-up. The expected occurrence of new depressive disorders during the follow-up interval was 
based on the age-specific incidence rates of the population-based NEMESIS study 70. In participants 
with obesity, hypertension or dyslipidemia at baseline, a 1.5-fold increased risk of depression would be 
detected with a probability >70% and 90% at the first and second follow-up, respectively. In 
participants with diabetes, a 1.75-fold increased risk for depression would be detected with a power of 
72% at the first und 96% at the second follow-up. The statistical power for mental disorders other 
than depression is lower because of their lower prevalence in the sample. However, with almost 34% 
of affected participants, analyses including the overall category of anxiety disorders had only a 
marginally smaller power than those involving depression (not shown). 
The power to detect differences between residents exhibiting a condition (specific mental disorder or 
CVRF) and those without this condition with respect to continuous outcome variables (e.g. scores or 
biological variables) was calculated according to the formula for continuous variables of Freeman 66 
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and assuming a sample size of 3400. This power depends upon both the prevalence of the syndrome 
and the expected effect size in terms of standard deviation (SD). Table 5 shows that even for rare 
conditions with a prevalence of 1% and 5%, the cohort provides sufficient power to detect distribution 
differences of 0.5 SD and 0.2 SD, respectively. 
  19 
Table 3 Power (%) for analyses including anxiety at baseline as independent variable and somatic cardiovascular risk factors or 
cardiovascular disease after 5-year and 10-year follow-up. 
 Cardiovascular risk factor CVD  Obesity Hypertension Diabetes Dyslipidemia 
Follow-up time (years) 5 10 5 10 5 10 5 10 5 10 
Expected sample size 2909 2994 2395 2465 3177 3270 2286 2353 3400 3500 
Expected number of cases with 
new CVRF among non anxious 
44 
(2.3%) 
83 
(4.2%) 
130 
(8.2%) 
241 
(14.8%) 
48 
(2.3%) 
86 
(4.0%) 
104 
(6.9%) 
205 
(13.2%) 
25 
(1.1%) 
46 
(2.0%) 
Expected power (%) 
RR=1.25 
RR=1.50 
RR=1.75 
RR=2.00 
 
16 
45 
73 
90 
 
26 
70 
94 
99 
 
39 
88 
99 
100 
 
66 
99 
100 
100 
 
17 
48 
77 
92 
 
27 
72 
95 
100 
 
32 
80 
98 
100 
 
58 
98 
100 
100 
 
11 
28 
50 
69 
 
17 
46 
75 
91 
 
CVD, cardiovascular disease; RR, relative risk. 
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Table 4 Power for analyses including somatic cardiovascular risk factors at baseline as 
independent variables and cardiovascular disease at the 5-year and 10-year 
follow-up as the dependent variable. 
 Obesity Hypertension Diabetes Dyslipidemia 
Follow-up time (years) 5 10 5 10 5 10 5 10 
Expected number of 
cases with new CVD 
among those not 
affected with the 
specific CVRF at 
baseline 
47 
(1.1%) 
77 
(2.0%) 
27 
(1.1%) 
44 
(2.0%) 
58 
(1.1%) 
95 
(2.0%) 
27 
(1.1%) 
44 
(2.0%) 
Expected power 
RR=1.25 
RR=1.50 
RR=1.75 
RR=2.00 
RR=2.50 
 
12 
29 
49 
68 
90 
 
15 
41 
67 
85 
98 
 
12 
31 
55 
75 
95 
 
17 
46 
75 
92 
100 
 
9 
20 
34 
48 
72 
 
11 
27 
46 
64 
87 
 
12 
31 
55 
75 
95 
 
17 
46 
75 
92 
100 
 
Table 5 Power for the analysis with continuous outcomes (%). 
Prevalence of the disorder Effect size (µ1-µ2)/s 
  0.1 0.2 0.3 0.5 1.0 
1% 9 22 42 84 100 
3% 17 52 86 100 100 
5% 25 73 97 100 100 
10% 43 94 100 100 100 
15% 56 99 100 100 100 
20% 66 100 100 100 100 
25% 73 100 100 100 100 
 
 
  21 
4 DISCUSSION 
The combined CoLaus/PsyCoLaus cohort provides a unique opportunity to obtain highly informative 
prospective data on the interplay between CVRF/CVD and mental disorders. Indeed, 
CoLaus/PsyCoLaus is currently the only existing study that brings together: 1) a thorough somatic 
investigation of CVRF, 2) an interview-based psychiatric evaluation, 3) the assessment of a 
comprehensive array of biological variables and 4) an extensive genome-wide genotyping in a large 
sample recruited from the general population. With the recent rapid progress in identifying genetic 
markers for complex diseases, we anticipate that numerous genetic markers for the index diseases in 
this study can also inform on the mechanisms of the associations between CVD/CVRF and mental 
disorders, as well as to predict risk for the development of these conditions. This will also enable us to 
identify gene-environment interactions underlying these diseases. A better understanding of the 
psychological, physiological and behavioral links underlying these conditions is expected to result in 
the development of more specific and efficient strategies of prevention and treatment for both 
psychiatric and CVD/CVRF, two major elements of the burden of disease. 
This study also provides an excellent opportunity to prospectively assess the long-term course and its 
determinants, clinical consequences as well as the type and duration of treatment of CVRF and mental 
disorders in the community. Service utilization patterns for these conditions will also provide 
important information for the development of health policy with focus on prevention. Indeed, 
regarding psychiatric conditions, follow-up data on the course of specific disorders in the general 
population based on large samples and contemporary methodology are still scarce. Moreover, the 
longitudinal data should also provide an important empirical basis for nosology. 
The proposed study together with the results of the recently initiated family study of the first-degree 
relatives of the CoLaus/PsyCoLaus sample will largely contribute to a better understanding of the 
nature of the comorbid associations between specific mental disorders and both CVRF and CVD. The 
increased knowledge of the psychological, physiological and behavioral links underlying CVRF/CVD 
and mental disorders is expected to result in the development of more specific and efficient strategies 
of prevention and treatment of both psychiatric and CVRF/CVD, two major elements of the burden 
of disease. 
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